ABCAM PLC Annual Financial Report (5814B)
September 21 2018 - 6:56AM
UK Regulatory
TIDMABC
RNS Number : 5814B
ABCAM PLC
21 September 2018
For immediate release 21 September 2018
ABCAM PLC
(the 'Company')
Publication of 2018 Annual Report and Accounts
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools, announces that its Annual
Report and Accounts for the year ended 30 June 2018 will be
published today on the Company's investor relations website,
www.abcamplc.com.
It will also be posted today, together with the Notice of Annual
General Meeting, to those shareholders that have elected to receive
paper communications. Shareholders that have not elected to receive
paper communications will be notified of the availability of these
documents on the Company's investor relations website,
www.abcamplc.com.
For further information please contact:
+ 44 (0) 1223 696
Abcam plc 000
Suzanne Smith, Company Secretary
James Staveley, Vice President Investor Relations
J.P.Morgan Cazenove - Nominated Advisor & + 44 (0) 20 7742
Corporate Broker 4000
James Mitford / Jonty Edwards
+ 44 (0) 20 3727
FTI Consulting 1000
About Abcam plc
As an innovator of reagents and tools, Abcam's purpose is to
serve life scientists globally to achieve their mission, faster.
Providing the research and clinical communities with tools and
scientific support, the Group offers highly validated biological
binders and assays to address important targets in critical
biological pathways.
A pioneer in data sharing and ecommerce in the life sciences,
Abcam's ambition is to be the most influential company in life
sciences by helping advance global understanding of biology and
causes of disease, which, in turn, will drive new treatments and
improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's antibodies and affinity binders, reagents,
biomarkers and assays and the Group's products are mentioned in
over 20,000 of the 56,000 peer-reviewed papers published each year
in the life sciences.
By actively listening to and collaborating with researchers, the
Group continuously advances its portfolio to address their needs. A
transparent programme of customer reviews and datasheets, combined
with an industry-leading validation initiative, gives researchers
increased confidence in their results.
Abcam's eleven locations are located in the world's leading life
science research hubs, enabling local services and multi-language
support. Founded in 1998 and headquartered in Cambridge, UK, the
Group sells to more than 100 countries. Abcam was admitted to AIM
in 2005 (AIM: ABC).
To discover more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSFKDDPDBKDQCB
(END) Dow Jones Newswires
September 21, 2018 07:56 ET (11:56 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024